BK1116 Health Care
- 2363.618
- +1.487+0.06%
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
Express News | Fosun Pharmaceuticals: The holding subsidiary was approved for clinical trials by the US FDA
Opinion | How much room is left for Hong Kong stocks after two weeks of sharp gains? Optimistic estimate: 20%!
If subsequent policies continue to be effective, profit growth of 10% under optimistic conditions will correspond to an increase of about 20%.
Express News | Morgan Stanley raised Fosun Pharmaceuticals' H-share rating to overrated.
Kanghua Healthcare (03689.HK) gains 482,800 shares by Mialkos Tomasz Jakub
Glonghui, May 3 | According to the Stock Exchange's latest equity disclosure, on April 26, 2024, Kanghua Healthcare (03689.HK) received Mialkos Tomasz Jakub to increase its holdings by 482,800 shares at an average price of HK$2.10 per share on the market, involving approximately HK$1.013,900. After the increase in holdings, the latest number of shares held by Mialkos Tomasz Jakub was 4.6874 million shares, and the shareholding ratio increased from 4.98% to 5.55%.
Express News | Hong Kong's Hang Seng Index closed up 2.5%, while the Hang Seng Technology Index closed up 4.45%. Shangtang closed up about 36%, NIO Auto closed up about 21%, Country Garden Service closed up about 13%, and Ali Health rose 11%.
Hong Kong Internet healthcare stocks continued to rise in the afternoon. Ali Health rose more than 9%, Jingdong Health rose nearly **** An Good Doctor rose nearly 8%, and Zhongan Online and Jingdang Health both rose more than 4%.
Hong Kong Internet healthcare stocks continued to rise in the afternoon. Ali Health rose more than 9%, Jingdong Health rose nearly **** An Good Doctor rose nearly 8%, and Zhongan Online and Jingdang Health both rose more than 4%.
Tong Ren Tang Registers Danggui Buxue Granules in Hong Kong
Beijing Tong Ren Tang Group (SHA:600085) received the certificate of registration from Hong Kong's Chinese Medicine Council for Danggui Buxue granules, according to the company's filing on the Shangha
華潤醫藥：公告有關於中國發行中期票據及公司債券的華潤醫藥控股截至2024年3月31日止三個月的未經審核財務業績
Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong
Beijing Tong Ren Tang Chinese Medicine (HKG:3613), a unit of Tong Ren Tang Technologies (HKG:1666), has obtained approval to sell its drug Danggui Buxue Keli in Hong Kong, a Tuesday filing by the latt
Hansoh Pharmaceutical's 2023 Profit Up 27%
Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s
Kanghua Healthcare (03689.HK) received 482,800 H shares from Tomasz Jakub Mialkos, worth approximately HK$1,013,900
On April 30, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 30, Tomasz Jakub Mialkos increased its holdings of $Kanghua Healthcare (03689.HK) H shares by 482,800 with an average price of HK$2.1 per share, worth about HK$1,013,900 on April 26. After the increase in holdings, Tomasz Jakub Mialkos's latest shareholding was 4.6874 million shares, and the good position ratio increased from 4.98% to 5.55%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, the majority shareholder
泰凌醫藥：2023 年報
Fosun Pharma's Q1 Profit Slumps 38%
Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) posted a net profit attributable to owners of 609.7 million yuan in the first quarter of 2024, slumping 38.2% from 987 million yuan a year
三生製藥：2023 年度報告
Tong Ren Tang's Q1 Profit Jumps 10%, Revenue Rises 2%
Beijing Tong Ren Tang Group's (SHA:600085) attributable net profit edged up 10% year over year in the first quarter to 575.9 million yuan from 523.4 million yuan a year earlier, the company said in a
Hanson Pharmaceuticals (03692): Tan Sihui has been appointed as Joint Company Secretary
Hanson Pharmaceuticals (03692) announced that Li Xinying has resigned as the company's joint company secretary and will no longer serve as the Hong Kong Joint Stock Company...
Hanson Pharmaceuticals (03692) will pay a final dividend of HK$0.1422 per share on July 17
Hanson Pharmaceuticals (03692) announced that the company will pay a final dividend of 0 per share on July 17, 2024...
翰森製藥：2023年報
Fosun Pharmaceutical (02196.HK): Fosun Pharmaceutical Industries and Kite Pharma plan to renew and provide additional loans totaling no more than 67 million US dollars to Fosun Kate based on their respective shareholding ratios
Fosun Pharmaceutical (02196.HK) announced that in order to meet the business plans and capital requirements of Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate”), it intends to request the shareholders' meeting of the company to approve the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as “Fosun Pharmaceutical Industry”) and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the other shareholder of Fosun Kate, and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the total renewal and additional provision of no more than 67 million yuan to Fosun Kate according to their respective shareholding shares in Fosun Kate Borrowings in US dollars (including principal amount) (